{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:47:25Z","timestamp":1790722045001,"version":"4.1.0"},"reference-count":41,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Obesity"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Obesity and its cardiovascular complications are major causes of morbidity and mortality. Little is known in real\u2010world settings about the effect of newly approved antiobesity medications (AOMs) on cardiovascular complications among patients with obesity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study examined the association between newly approved AOM use and cardiovascular events among Medicare patients with obesity using data from 2020 to 2022. Patient age, gender, comorbidity scores, socioeconomic status, and baseline cardiovascular comorbidities were compared descriptively. Subgroup analysis compared variables by medication type. Relative risk and absolute risk of cardiovascular disease (CVD) events were estimated using Cox and Aalen regression models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The analysis included 5926 patients treated with semaglutide and tirzepatide, including Ozempic (5404 patients), Wegovy (375 patients), or Mounjaro (147 patients). Hypertension, type 2 diabetes, and hyperlipidemia were the most common comorbidities. For patients with AOMs, less incidence of heart failure (4.89% vs. 6.13%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), atrial fibrillation (3.83% vs. 5.17%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), arrhythmia (3.59% vs. 4.14%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0153), and peripheral vascular disease (3.44% vs. 2.94%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0395) was found versus patients without AOMs. Patients receiving AOMs showed an 8% risk reduction in any CVD. Protective effect on CVD was apparent over the first 375\u2009days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Results suggest that utilization of AOMs effectively alleviates the high prevalence of CVD.<\/jats:p><\/jats:sec>","DOI":"10.1002\/oby.24037","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T07:48:47Z","timestamp":1714981727000},"page":"1401-1409","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["The association between weight loss medications and cardiovascular complications"],"prefix":"10.1002","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7447-5672","authenticated-orcid":false,"given":"Onur","family":"Baser","sequence":"first","affiliation":[{"name":"Department of Economics Bogazici University  Istanbul Turkey"},{"name":"Graduate School of Public Health City University of New York  New York New York USA"},{"name":"Department of Internal Medicine University of Michigan Medical School  Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Samayoa","sequence":"additional","affiliation":[{"name":"Columbia Data Analytics  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Rodchenko","sequence":"additional","affiliation":[{"name":"Columbia Data Analytics  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Isenman","sequence":"additional","affiliation":[{"name":"Columbia Data Analytics  Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdem","family":"Baser","sequence":"additional","affiliation":[{"name":"Columbia Data Analytics  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehir","family":"Yapar","sequence":"additional","affiliation":[{"name":"Columbia Data Analytics  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272\u2010022\u201000532\u2010z"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586\u2010022\u201004505\u20107"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573\u2010021\u201000337\u20108"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1095753"},{"key":"e_1_2_11_6_1","unstructured":"Kolata G.We know where new weight loss drugs came from but not why they work.The New York Times. August 17 2023. Accessed November 3 2023.https:\/\/www.nytimes.com\/2023\/08\/17\/health\/weight\u2010loss\u2010drugs\u2010obesity\u2010ozempic\u2010wegovy.html"},{"key":"e_1_2_11_7_1","unstructured":"FDAapproves new drug treatment for chronic weight management first since 2014. News release. June 4 2021. Accessed November 28 2023.https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010new\u2010drug\u2010treatment\u2010chronic\u2010weight\u2010management\u2010first\u20102014"},{"key":"e_1_2_11_8_1","unstructured":"Lillyreceives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity or overweight with weight\u2010related comorbidities. News release. October 6 2022. Accessed November 2 2022.https:\/\/investor.lilly.com\/news\u2010releases\/news\u2010release\u2010details\/lilly\u2010receives\u2010us\u2010fda\u2010fast\u2010track\u2010designation\u2010tirzepatide"},{"key":"e_1_2_11_9_1","unstructured":"AlecciaJ;Associated Press. FDA approves new version of diabetes drug Mounjaro to be sold for weight loss. PBS NewsHour. November 8 2023. Accessed November 22 2023https:\/\/www.pbs.org\/newshour\/politics\/fda\u2010approves\u2010new\u2010version\u2010of\u2010diabetes\u2010drug\u2010mounjaro\u2010to\u2010be\u2010sold\u2010for\u2010weight\u2010loss"},{"key":"e_1_2_11_10_1","unstructured":"WardC EwaldE KoenigK.Schluterman N. Prevalence and health care expenditures among Medicare beneficiaries aged 65\u2009years and over with heart conditions. Data Highlight. Centers for Medicare and Medicaid Services;2017.https:\/\/www.cms.gov\/Research\u2010Statistics\u2010Data\u2010and\u2010Systems\/Research\/MCBS\/Downloads\/HeartConditions_DataBrief_2017.pdf"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.36469\/001c.87538"},{"key":"e_1_2_11_12_1","unstructured":"Kythera. Accessed September 12 2023.https:\/\/www.kytheralabs.com\/"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejm200107123450205"},{"key":"e_1_2_11_14_1","first-page":"188","article-title":"Charlson Comorbidity Index: ICD\u20109 update and ICD\u201010 translation","volume":"12","author":"Glasheen WP","year":"2019","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001648\u2010200205000\u201000016"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/0470011815.b2a11002"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102458\u20109\u201088"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.07.763"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(09)60318\u20104"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10\u20102415"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000000973"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.117.029652"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp19x702725"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.067505"},{"key":"e_1_2_11_26_1","unstructured":"American Heart Association.Cardiovascular Disease: A Costly Burden for America Projections Through 2035. Accessed November 15 2023.https:\/\/www.heart.org\/\u2010\/media\/Files\/About\u2010Us\/Policy\u2010Research\/Fact\u2010Sheets\/Public\u2010Health\u2010Advocacy\u2010and\u2010Research\/CVD\u2010A\u2010Costly\u2010Burden\u2010for\u2010America\u2010Projections\u2010Through\u20102035.pdf"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.108.821306"},{"key":"e_1_2_11_29_1","unstructured":"Centers for Disease Control and Prevention.Heart disease facts. Updated May 15 2023. Accessed November 15 2023.https:\/\/www.cdc.gov\/heartdisease\/facts.htm"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd6020019"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000000659"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2020.02.47"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192895"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573403x16999201210200342"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.7326"},{"key":"e_1_2_11_36_1","unstructured":"World Health Organization.Cardiovascular diseases (CVDs). Published June 11 2021. Accessed November 15 2023.https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds)"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.120.053216"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2011.10.003"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11111529"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwj313"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.2105\/ajph.2003.032482"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.22034\/apjcp.2017.18.4.1077"}],"container-title":["Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/oby.24037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T03:37:58Z","timestamp":1720409878000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/oby.24037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1002\/oby.24037"],"URL":"https:\/\/doi.org\/10.1002\/oby.24037","archive":["Portico"],"relation":{},"ISSN":["1930-7381","1930-739X"],"issn-type":[{"value":"1930-7381","type":"print"},{"value":"1930-739X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]},"assertion":[{"value":"2023-12-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}